000 | 01950 a2200541 4500 | ||
---|---|---|---|
005 | 20250517013840.0 | ||
264 | 0 | _c20150528 | |
008 | 201505s 0 0 eng d | ||
022 | _a1098-5514 | ||
024 | 7 |
_a10.1128/JVI.02904-14 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aGupta, Sachin | |
245 | 0 | 0 |
_aDNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. _h[electronic resource] |
260 |
_bJournal of virology _cApr 2015 |
||
300 |
_a4158-69 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural | ||
650 | 0 | 4 |
_aAIDS Vaccines _ximmunology |
650 | 0 | 4 |
_aAdjuvants, Immunologic _xpharmacology |
650 | 0 | 4 | _aAnalysis of Variance |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntibodies, Neutralizing _xdrug effects |
650 | 0 | 4 |
_aB-Cell Activating Factor _ximmunology |
650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
650 | 0 | 4 | _aEnzyme-Linked Immunospot Assay |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFlow Cytometry |
650 | 0 | 4 |
_aHIV Envelope Protein gp120 _xdrug effects |
650 | 0 | 4 |
_aHIV Infections _xprevention & control |
650 | 0 | 4 |
_aHIV-1 _ximmunology |
650 | 0 | 4 |
_aInterleukin-12 _ximmunology |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Inbred BALB C |
650 | 0 | 4 | _aNeutralization Tests |
650 | 0 | 4 |
_aPlasmids _xgenetics |
650 | 0 | 4 |
_aTumor Necrosis Factor Ligand Superfamily Member 13 _ximmunology |
650 | 0 | 4 |
_aVaccines, DNA _ximmunology |
700 | 1 | _aClark, Emily S | |
700 | 1 | _aTermini, James M | |
700 | 1 | _aBoucher, Justin | |
700 | 1 | _aKanagavelu, Saravana | |
700 | 1 | _aLeBranche, Celia C | |
700 | 1 | _aAbraham, Sakhi | |
700 | 1 | _aMontefiori, David C | |
700 | 1 | _aKhan, Wasif N | |
700 | 1 | _aStone, Geoffrey W | |
773 | 0 |
_tJournal of virology _gvol. 89 _gno. 8 _gp. 4158-69 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1128/JVI.02904-14 _zAvailable from publisher's website |
999 |
_c24574749 _d24574749 |